Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,583 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07377279Recruiting
Acupuncture and compression to prevent nerve pain from chemo
This trial tests whether acupuncture and compression therapy can prevent nerve damage caused by taxane chemotherapy in early-stage breast cancer. It aims to reduce numbness, tingling, or pain in the hands and feet.
Guangzhou, GuangdongAges 18–70 - NCT07376837Recruiting
Radiofrequency ablation for small low-risk thyroid cancer
This study tests whether radiofrequency ablation (a heat-based treatment applied through the skin) can safely and effectively cure small, low-risk papillary thyroid cancers. It is designed for people whose tumors are small, have not spread, and who either cannot have surgery or prefer not to.
Toronto, OntarioAges 18 years+ - NCT07371208RecruitingPhase 2
Sac-TMT plus immunotherapy before surgery for triple-negative breast cancer
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07376681Enrolling by invitation
Fertility in young breast cancer patients
This study looks at fertility, cancer outcomes, and children's health in women diagnosed with breast cancer at age 40 or younger. It aims to help you understand how breast cancer and its treatment may affect your ability to have children and your long-term health.
Taizhou, ZhejiangAges 18–40 - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07363382RecruitingPhase 1/Phase 2
Testing GRPR PET Scan for Prostate Cancer
This study tests a new imaging method (GRPR PET) to help better see and stage prostate cancer. If you have prostate cancer, this scan may give doctors more detail about where the cancer is located.
Fuzhou, FujianAges 18–90 - NCT07362342Recruiting
Right heart function after lung lobe removal surgery
This study looks at how the right side of the heart handles the stress of having a lung lobe removed. It compares different surgery types (VATS, robotic, or open) and focuses on people with moderate to high heart and lung risk factors.
Rozzano, MIAges 18 years+ - NCT07369427Recruiting
Magnetic tracking and ECG guidance for PICC placement
This trial tests a system that uses magnetic tracking and ECG signals to help guide the placement of a PICC line (a thin tube for delivering medication) in cancer patients. It aims to make the insertion safer and more accurate, especially for those at high risk for blood clots.
Guangzhou, GuangdongAges 18–80 - NCT07363486RecruitingPhase 1/Phase 2
Study of 225Ac-LNC1011 for advanced prostate cancer
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
Fuzhou, FujianAges 18–90 - NCT07368998RecruitingPhase 2
Study of inavolisib plus fulvestrant for advanced breast cancer
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07367516RecruitingPhase 1/Phase 2
A new study of TQB6411 for esophageal cancer
This study tests an experimental drug, TQB6411, for people with esophageal cancer that has come back or spread. It may be an option if previous treatments, including immunotherapy and chemotherapy, have stopped working or caused side effects.
Hefei, AnhuiAges 18–75 - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Los Angeles, CaliforniaAges 2–17 - NCT03957902RecruitingPhase 2
Aspirin blood markers to guide prevention after colon cancer
This Phase 2 trial studies how aspirin affects specific “biomarkers” (measurable body signals) in people newly diagnosed with colon or rectal cancer. The goal is to see whether aspirin-related changes can help design more personalized prevention treatment plans.
Zaragoza, ZaragozaAges 18–79 - NCT05319639RecruitingPhase 1/Phase 2
Irinotecan plus immunotherapy for stomach cancer
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Fuzhou, FujianAges 18–75 - NCT06783829RecruitingPhase 1
Study of SHR-4394 for men with advanced prostate cancer
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
Chengdu, SichuanAges 18–85 - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06763029RecruitingPhase 2
Study of three drugs for advanced colorectal cancer after first treatment
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT07361107RecruitingPhase 1
Immune response study of histotripsy in colorectal cancer
This trial tests how your body's immune system reacts to a treatment called histotripsy for colorectal cancer that has spread to the liver. Histotripsy uses sound waves to break apart tumors, and the study aims to see if this can help your immune system fight the cancer better.
New Hyde Park, New YorkAges 18 years+ - NCT07359235RecruitingPhase 1
KD01 for bladder cancer: a safety and early efficacy trial
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
Wuhan, HubeiAges 18–75 - NCT07354100RecruitingPhase 1/Phase 2
Lactulose to boost gut health during immunotherapy
This study tests whether a simple sugar syrup called lactulose can improve gut health and make immunotherapy work better for certain cancers. Lactulose is taken by mouth along with your regular immunotherapy.
Chicago, IllinoisAges 18 years+ - NCT07359989Recruiting
Leucine plus chemoradiation before surgery for rectal cancer
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
Hangzhou, ZhejiangAges 18–80 - NCT07353723RecruitingPhase 2
Combination therapy for advanced tonsil cancer
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
Shanxi, ProvinceAges 18–80
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,583 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.